Publication | Closed Access

Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial

UrologyHepatologyMedicineKeynote-426 TrialHepatotoxicityPharmacotherapyLiver CancerOncologyRadiation OncologyTreatment-emergent Hepatic Toxicity